IWA
VRTX icon

Icon Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Icon Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
2,283
-1,482
-39% -$657K 0.07% 173
2026
Q1 		$1.59M Buy
3,765
+22
+0.6% +$10.3K 0.1% 128
2025
Q4 		$1.7M Buy
3,743
+176
+5% +$75.9K 0.11% 126
2025
Q3 		$1.4M Buy
3,567
+982
+38% +$410K 0.09% 148
2025
Q2 		$1.15M Buy
2,585
+88
+4% +$40.6K 0.08% 154
2025
Q1 		$1.21M Buy
2,497
+245
+11% +$114K 0.1% 141
2024
Q4 		$907K Sell
2,252
-151
-6% -$70K 0.07% 154
2024
Q3 		$1.12M Buy
2,403
+83
+4% +$39.9K 0.09% 143
2024
Q2 		$1.15M Sell
2,320
-315
-12% -$137K 0.1% 140
2024
Q1 		$1.1M Sell
2,635
-50
-2% -$21.1K 0.1% 137
2023
Q4 		$1.09M Buy
+2,685
New +$992K 0.11% 120
2022
Q4 		$858K Sell
2,970
-129
-4% -$39.3K 0.1% 149
2022
Q3 		$897K Buy
+3,099
New +$892K 0.11% 141

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Icon Wealth Advisors's VRTX Position: Q2 2026 in Review

Icon Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 39% in Q2 2026, selling an estimated $657K and leaving 2,283 shares worth $1.13M. The position accounts for 0.07% of the portfolio, ranked #173.

Icon Wealth Advisors first reported a position in VRTX in Q3 2022 and has held it in 13 quarters since. The position peaked at $1.7M in Q4 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Icon Wealth Advisors held 2,283 shares of Vertex Pharmaceuticals worth $1.13M as of Q2 2026.
  • Icon Wealth Advisors sold 1,482 Vertex Pharmaceuticals shares in Q2 2026, an estimated $657K.
  • Vertex Pharmaceuticals made up 0.07% of Icon Wealth Advisors's portfolio in Q2 2026, its #173 holding.
  • Icon Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • Icon Wealth Advisors's Vertex Pharmaceuticals position peaked at $1.7M in Q4 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Icon Wealth Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.